Robert A. Wermers, M.D.

Closed for Enrollment

• A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 in Adults With ENPP1 Deficiency (ENPP-INZ) Rochester, Minn.

  The purpose of this study is to assess safety and tolerability of INZ-701, a recombinant Ectonucleotide Pyrophosphatase/Phosphodiesterase (ENPP1) enzyme, for the treatment of ENPP1 deficiency. The study also aims to establish the safety and tolerability of multiple ascending subcutaneous (SC) doses of INZ-701.

• Denosumab Stimulated Parathyroid Scan Pilot Study in Persistent or Recurrent Primary Hyperparathyroidism Rochester, Minn.

  The purpose of this study is to determine if denosumab prior to parathyroid scan in patients with recurrent or persistent primary hyperparathyroidism and osteoporosis or osteopenia improves localization of parathyroid adenomas.

• Prevalence of Hypophosphatasia in Patients with Fibromyalgia at the Mayo Clinic Rochester, Minn.

  The overall goal of this research is to identify patients in clinical practice that have unrecognized hypophosphatasia (HPP) and select appropriate candidates for therapy. The purpose of this proposal is to identify the prevalence of adults with hypophosphatasia within a previously identified fibromyalgia cohort at our institution.